Eisbach
Eisbach Bio is a clinical-stage biotechnology company based in Munich that uses AI-enabled discovery to develop next-generation small-molecule cancer therapies targeting the activated state of enzymes.
Classification
Profile
Funding
Funding details not yet available.
Develops next-generation small-molecule cancer therapies by targeting the activated state of enzymes using the proprietary AI-guided ALLOS platform.
B2B, pharmaceutical partnerships, healthcare providers, research institutions
Licensing & royalty agreements with pharma partners for lead and pipeline candidates · Milestone payments tied to IND filing, Phase I/II completions, and regulatory approvals · Strategic equity financing (venture capital, state grants)
Direct B2B outreach - scientific conferences (ASCO, AACR), biotech matchmaking events (Munich Startup Day) · Digital presence - corporate website, LinkedIn, Twitter (active engagement with research community) · Academic collaborations - joint projects with the Biomedical Center Munich and university labs
Spin-out from the Biomedical Center, leveraging academic origins for its scientific foundation.
R&D for AI-enabled discovery and clinical-stage development of small-molecule therapies targeting tumor growth and resistance mechanisms.
Proprietary ALLOS platform, AI-guided molecular approaches, and specialized team led by CEO Dr. Adrian Schomburg.
AI-enabled discovery and development of innovative therapies addressing core mechanisms of tumor growth and resistance.
Scientific partnership model - co-development agreements, data-sharing, joint publications · Investor relations - quarterly updates, transparent financial reporting, participation in biotech pitch events · Patient-advocacy liaison - advisory boards with patient groups to shape trial design and endpoint relevance
Competes in clinical-stage biotechnology by targeting enzyme activation states, differentiating via AI-guided molecular approaches.
Core mechanisms of tumor growth and resistance in oncology that current therapies fail to adequately address.
No investors recorded yet.